1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Clinical Laserthermia Systems AB Class B

Clinical Laserthermia Systems AB Class B

8.19
SEK
-0.06
(-0.73%)
-5.92EPS
Nov 13Next Earn
Clinical Laserthermia Systems AB Class B
STO:CLS_BTU_B
(Nasdaq Stockholm)

Recent

price

8.19

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
6.42
- -
- -
- -
- -
- -
- -
4.52
11.85
8.88
6.73
10.78
63.85
5.26
7.52
2.98
1.86
Revenue per Share
-91.29
-113.53
-152.62
-206.11
-203.89
-159.33
-240.33
-156.56
-215.4
-270.03
-292.88
-305.34
-719.79
-50.76
-19.07
-7.09
-5.86
Basic EPS, GAAP
-125.24
-126.13
-169.55
-234.39
-207.5
-197.54
-188.78
-213.96
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
189.76
176.29
210.31
293.45
360.84
186.84
142.39
236.72
299.35
41.94
66.13
73.95
19.54
29.11
15.03
9.86
6.77
Book Value per Share
40.16
14.5
65.97
133.98
171.23
9.32
-24.76
66.55
142.77
-100.2
-34.76
7.47
-17.9
17.1
12.08
8.26
5.31
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
2
6
7
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
1
2
1
1
2
6
8
19
17
13
Sales/Revenue/Turnover
-1,412.34
- -
- -
- -
- -
- -
- -
-3,388.17
-1,845.47
-2,967.53
-3,889.7
-2,699.98
-1,075.95
-791.51
-288.71
-165.5
-328.2
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
3
3
2
3
3
3
3
Depreciation Expense
-5
-7
-13
-18
-18
-17
-27
-21
-33
-43
-58
-64
-71
-80
-48
-42
-39
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,420.99
- -
- -
- -
- -
- -
- -
-3,463.03
-1,817.2
-3,041.73
-4,349.77
-2,833.63
-1,127.31
-964.49
-253.54
-237.96
-314.55
Profit Margin (%)
2
1
5
12
15
1
-3
10
24
-19
-9
-3
-17
13
26
29
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
- -
- -
- -
- -
LT Debt
10
11
17
26
32
19
17
33
50
7
14
21
8
44
66
66
44
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-58.63
-65.9
-90.94
-84.87
-61.88
-65.03
-147.57
-84.95
-79.36
-152.72
-553.78
-356.17
-455.71
-290.23
-83.19
-60.14
-68.65
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
- -
- -
- -

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
39
29
24
Cash, Cash Equivalents & STI
22
13
4
Accounts Receivable, Net
3
1
6
Inventories
10
10
9
Total Current Liabilities
10
10
25
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
63.99%
98.96%
1.21%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
14.23%
-3.83%
-12.62%
Sales/Revenue/Turnover
- -
79.97%
-6.9%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3
6
5
5
19
2025
4
9
3
1
17
2026
1
8
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-8.33
-4.3
-4.41
-2.65
-19.07
2025
-3.15
-1.1
-1.4
-1.7
-7.09
2026
-1.04
-1.71
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Clinical Laserthermia Systems AB (publ) Clinical Laserthermia Systems AB (publ) develops and sells medical devices for minimally invasive laser ablation of diseased tissue, including cancer tumors, brain tumors, and drug-resistant epilepsy foci; its core TRANBERG Thermal Therapy System includes a mobile 1064-nanometer laser unit, Thermoguide Workstation for real-time MRI-compatible temperature monitoring and treatment control, various gauge laser applicators, and sterile single-use disposables; the company also supplies components for the ClearPoint Prism Neuro Laser Therapy System in partnership with ClearPoint Neuro, Inc. Founded in 2006 and headquartered in Lund, Sweden, Clinical Laserthermia Systems AB (publ) operates primarily in the medical equipment sector with regulatory approvals in the EU and US, targeting urology, neurosurgery, and interventional oncology professionals; it maintains subsidiaries in Germany, the US, and Singapore to support global commercialization in Europe, North America, and Asia. The company pursues immunostimulating laser thermotherapy (imILT) for potential abscopal immune effects alongside focal ablation for low-to-intermediate risk prostate cancer, glioblastoma, and epileptic foci. Recent developments include a SEK 20.9 million warrant exercise in September 2025 and a prior SEK 16 million directed unit issue in February 2025 to fund neurosurgery partnerships and commercialization; in April 2025, its partner ClearPoint Neuro submitted a 510(k) to the FDA to expand ClearPoint Prism indications to 1.5T MRI guidance, targeting over 50% of the neuro LITT market; the company received a SEK 5.5 million order for ClearPoint Prism products, sponsored clinical trials such as Phase I prostate studies with Focalyx Technologies and Genesis Research using TRANBERG systems, and entered evaluation agreements with Skåne University Hospital for glioblastoma laser ablation and HALO Diagnostics for prostate cancer.